| 0187 Weekly docetaxel with or without gemcitabine as second line chemotherapy in paclitaxel pretreated patients with metastatic breast cancer: A randomised phase II study … F Zagouri, A Bamias, P Papakostas, A Karadimou, E Bournakis, ... The Breast, S66, 2009 | | 2009 |
| 1 Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma Pavlos Msaouel, Andrew L. Hong … H Grodman, JS Dome, CV Fernandez, JI Geller, AB Apolo, NC Daw, ... | | |
| 103. The prognostic significance of chemotherapy response score and lymphocytic infiltration in patients with ovarian cancer treated with neoadjuvant chemotherapy J Rodolakis, A Prodromidou, N Thomakos, M Sotiropoulou, M Liontos, ... European Journal of Obstetrics and Gynecology and Reproductive Biology 270, e34, 2022 | | 2022 |
| 1086 Biochemical markers of bone remodeling as predictors of skeletal morbidity and outcome in patients with solid tumors metastatic to the skeleton receiving the biphosphonate … G Mountzios, MA Dimopoulos, A Bamias, M Mavrikakis, K Syrigos, ... EJC Supplements 2 (7), 110-111, 2009 | | 2009 |
| 1735O PD-L1 expression on immune cells by SP142 co-localises with dendritic cells and is associated with improved overall survival (OS) with atezolizumab in patients with … EG Pulido, MD Galsky, R Van Elzen, R Banchereau, M Peterson, ... Annals of Oncology 33, S1329, 2022 | 3 | 2022 |
| 1897P Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations F Massari, EG Pulido, A Bamias, R Iacovelli, JM Cerrillo, G Procopio, ... Annals of Oncology 34, S1021, 2023 | | 2023 |
| 2022-RA-1453-ESGO Chemotherapy response score as a predictor of survival among patients undergoing interval debulking surgery for ovarian cancer I Rodolakis, M Liontos, K Papadatou, A Prodromidou, D Haidopoulos, ... International Journal of Gynecological Cancer 32 (Suppl 2), A338-A338, 2022 | | 2022 |
| 212P: 2nd line chemotherapy in malignant mesothelioma: A center's experience D Vassos, G Tsironis, A Kopitopoulou, S Tsagkouli, S Tsimpoukis, ... Journal of Thoracic Oncology 11 (4), S148-S149, 2016 | | 2016 |
| 217 The impact of chemotherapy response score and lymphocytic infiltration in patients with ovarian cancer treated with neoadjuvant chemotherapy I Rodolakis, A Prodromidou, M Sotiropoulou, M Liontos, D Haidopoulos, ... International Journal of Gynecologic Cancer 31 (Suppl 3), 2021 | | 2021 |
| 24-hour arterial blood pressure monitoring in patients with renal cell carcinoma treated with sunitinib results in control of hypertension without dose reduction in the … G Lainakis, A Barrias, E Manios, E Koroboki, M Migkou, R Giftaki, ... ANNALS OF ONCOLOGY 19, 195-195, 2008 | 2 | 2008 |
| 2409TiP A global, multicentre, open-label, randomised phase II trial of tobemstomig (tobe) with or without tiragolumab (tira) vs atezolizumab (atezo) in patients (pts) with … S Gupta, O Alhalabi, A Bamias, J Bellmunt, DEC Gauna, J Bedke, ... Annals of Oncology 34, S1225, 2023 | 1 | 2023 |
| 2607 Predicting venous thromboembolism (VTE) in metastatic urothelial tract tumors (UTT) J Ramos, M Casey, A Bamias, U De Giorgi, J Bellmunt, L Harshman, ... European Journal of Cancer 3 (51), S514, 2015 | | 2015 |
| 2608 A retrospective study of vascular thromboembolic events (VaTEs) in patients receiving first line treatment for advanced urothelial cancer (AUC) I Dimitriadis, G Tsironis, K Tzannis, K Koutsoukos, E Kostouros, M Liontos, ... European Journal of Cancer 3 (51), S514, 2015 | | 2015 |
| 2702 Safety and efficacy in ROSiA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC) AM Oza, F Selle, I Davidenko, J Korach, C Mendiola, P Gocze, P Pautier, ... European Journal of Cancer 3 (51), S532, 2015 | 3 | 2015 |
| 5003 ORAL A randomised phase II study of carboplatin plus liposomal doxorubicin (CLD) vs carboplatin plus paclitaxel (CP) in potentially platinum sensitive ovarian cancer … H Linardou, D Bafaloukos, A Bamias, I Xanthakis, HP Kalofonos, ... EJC Supplements 4 (5), 312, 2007 | | 2007 |
| 5040 POSTER Recurrent or metastatic endometrial cancer: Prognostic factors after taxane-based systemic chemotherapy G Mountzios, A Bamias, D Papadimitriou, E Pissakas, G Bozas, ... EJC Supplements 4 (5), 322, 2007 | | 2007 |
| 629P Neutrophil-lymphocyte ratio (NLR) as a prognostic and predictive biomarker in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with … R de Wit, C Wülfing, DC Gauna, G Kramer, JC Eymard, CN Sternberg, ... Annals of Oncology 31, S519-S520, 2020 | 1 | 2020 |
| 658MO Cisplatin (cis)-related immunomodulation and efficacy with atezolizumab (atezo)+ cis-vs carboplatin (carbo)-based chemotherapy (chemo) in metastatic urothelial cancer (mUC) MD Galsky, X Guan, R Banchereau, L Wang, J Zhu, H Yu, D Rishipathak, ... Annals of Oncology 32, S682-S683, 2021 | 16 | 2021 |
| 697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable … TB Powles, MS Van Der Heijden, DC Gauna, Y Loriot, MD Galsky, ... Annals of Oncology 31, S550-S551, 2020 | 19 | 2020 |
| 698O Patient-reported outcomes (PROs) from IMvigor130: A global, randomised, partially blinded phase III study of atezolizumab (atezo)+ platinum-based chemotherapy (PBC) vs … A Bamias, M De Santis, JÁ Arranz, E Grande, MD Galsky, E Kikuchi, ... Annals of Oncology 31, S551-S552, 2020 | 10 | 2020 |
